Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NLRP3 | Q96P20 | 9/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.42 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.42 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.40 |
| ▸ | RORC | P51449 | 2/20 | 0.39 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.39 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.39 |
| ▸ | CFTR | P13569 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22802359 | 0.87 | NLRP3 (0.55) | NLRP3ALDH1A1KDM4EMEN1KMT2A | |
| SCHEMBL22802377 | 0.86 | NLRP3 (0.54) | NLRP3ALDH1A1NPC1AKR1C3AKR1C2 | |
| SCHEMBL23012726 | 0.81 | NLRP3 (0.47) | NLRP3KDM4E | |
| SCHEMBL29691373 | 0.81 | NLRP3 (0.47) | NLRP3KDM4E | |
| SCHEMBL22866987 | 0.77 | NLRP3 (0.69) | NLRP3 | |
| SCHEMBL22866644 | 0.77 | NLRP3 (0.66) | NLRP3AKR1C3AKR1C2RORC | |
| SCHEMBL29691391 | 0.76 | NLRP3 (0.38) | NLRP3 | |
| SCHEMBL23012269 | 0.76 | NLRP3 (0.38) | NLRP3 | |
| SCHEMBL22802393 | 0.75 | NLRP3 (0.49) | NLRP3AKR1C3AKR1C2AAK1 | |
| SCHEMBL30163219 | 0.75 | NLRP3 (0.49) | NLRP3AKR1C3AKR1C2AAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12030879-B2 | Sulfonyl acetamides as NLRP3 inhibitors | INFLAZOME LIMITED (IE) | 2024-07-09 | — | — | US | disclosed |
| US-11884645-B2 | Sulfonyl acetamides as NLRP3 inhibitors | INFLAZOME LIMITED (IE) | 2024-01-30 | — | — | US | disclosed |
| US-11530200-B2 | Compounds | INFLAZOME LIMITED (IE) | 2022-12-20 | — | — | US | disclosed |
| US-11530200-B2 | Compounds | INFLAZOME LIMITED (IE) | 2022-12-20 | — | — | US | disclosed |
| US-20210047302-A1 | NOVEL COMPOUNDS | INFLAZOME LIMITED (IE) | 2021-02-18 | — | — | US | disclosed |
| US-20210047302-A1 | NOVEL COMPOUNDS | INFLAZOME LIMITED (IE) | 2021-02-18 | — | — | US | disclosed |
| US-20210002274-A1 | NOVEL COMPOUNDS | INFLAZOME LIMITED (IE) | 2021-01-07 | — | — | US | disclosed |
| US-20210002274-A1 | NOVEL COMPOUNDS | INFLAZOME LIMITED (IE) | 2021-01-07 | — | — | US | disclosed |
| EP-3759090-A1 | NOVEL COMPOUNDS | Inflazome Limited (IE) | 2021-01-06 | — | — | EP | disclosed |
| EP-3759078-A1 | NOVEL COMPOUNDS | Inflazome Limited (IE) | 2021-01-06 | — | — | EP | disclosed |
| EP-3759103-A1 | NOVEL COMPOUNDS | Inflazome Limited (IE) | 2021-01-06 | — | — | EP | disclosed |
| US-20200399243-A1 | NOVEL COMPOUNDS | INFLAZOME LIMITED (IE) | 2020-12-24 | — | — | US | disclosed |
| US-20200399243-A1 | NOVEL COMPOUNDS | INFLAZOME LIMITED (IE) | 2020-12-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210047302-A1 | NOVEL COMPOUNDS | NLRP3, NOD1, CBR3 | NLRP3 1/4885ALDH1A1 1532/4885KDM4E 3268/4885 |
| US-12030879-B2 | Sulfonyl acetamides as NLRP3 inhibitors | NLRP3, NOD1, NLRP1 | NLRP3 1/4885ALDH1A1 1078/4885KDM4E 2211/4885 |
| US-20200399243-A1 | NOVEL COMPOUNDS | NLRP3, NOD1, NLRP1 | NLRP3 1/4885ALDH1A1 1059/4885KDM4E 3031/4885 |
| US-11884645-B2 | Sulfonyl acetamides as NLRP3 inhibitors | NLRP3, NOD1, ABCC5 | NLRP3 1/4885ALDH1A1 966/4885KDM4E 2934/4885 |
| US-20210002274-A1 | NOVEL COMPOUNDS | NLRP3, NOD1, NLRP1 | NLRP3 1/4885ALDH1A1 1160/4885KDM4E 2915/4885 |
| US-11530200-B2 | Compounds | NLRP3, NOD1, NLRP1 | NLRP3 1/4885ALDH1A1 1220/4885KDM4E 3491/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.